Loading the public record
Loading the public record
Where They Stand is a nonpartisan guide to everyone running for Congress: their money, their own words and how incumbents voted. Find your ballot →
All recent votes113th CongressHouse
(This measure has not been amended since it was introduced. The expanded summary of the Senate reported version is repeated here.)
Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013 - Title I: Fees Relating to Animal Drugs - Animal Drug User Fee Amendments of 2013 - (Sec. 103) Amends the Federal Food, Drug, and Cosmetic Act to extend for FY2014-FY2018 the authority of the Food and Drug Administration (FDA) to collect animal drug user fees, specifically new animal drug application or supplemental animal drug application fees, animal drug product fees, animal drug establishment fees, and animal drug sponsor fees.
Revises the due date for annual user fees to the later of January 31 of each year or the first business day after enactment of an appropriations act providing for the collection and obligation of fees for the fiscal year.
Establishes the amount of revenue such fees can generate. Specifies percentages of the total revenue that shall be derived from each type of user fee.
Requires the Secretary of Health and Human Services (HHS) to adjust the total revenue amounts for FY2015 and subsequent fiscal years for inflation.
Authorizes the Secretary to accept payment of user fees prior to their due date.
Requires the total fees collected for FY2016-FY2018 to be increased by the cumulative amount, if any, by which the amount of user fees collected and appropriated for prior fiscal year falls below the cumulative amount of fees authorized.
(Sec. 104) Extends requirements for the FDA to report to Congress on achieving goals related to animal drug development and review processes and implementation of authority to collect animal drug user fees.
(Sec. 107) Terminates the authority to collect user fees October 1, 2018.
Title II: Fees Relating to Generic Animal Drugs - Animal Generic Drug User Fee Amendments of 2013 - (Sec. 202) Extends for FY2014-FY2018 the authority of the FDA to collect generic animal drug user fees, specifically abbreviated application fees for generic new animal drugs, generic new animal drug product fees, and generic new animal drug sponsor fees.
Subjects generic animal drug applications to a fee 50% of the amount of the normal fee if the application is for an animal drug which contains more than one active ingredient, or the labeling of the drug prescribes, recommends, or suggests use of the drug in combination with one or more other animal drugs, and the active ingredients or drugs intended for use in the combination have previously been separately approved.
Revises the due date for annual generic animal drug user fees to the later of January 31 of each year or the first business day after enactment of an appropriations act providing for the collection and obligation of fees for the fiscal year.
House Jun 3, 2013
Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013
Passed · Two-thirds required
390 Yea 12 Nay 31 not voting
Crossed both parties 12 of 402 voting members broke with their own party: 12 Democrats.
DemocratsRepublicansFilled: YeaRing: NayGrey: not voting or present
433 members on this roll call, from the official House record. Party majorities need at least five voting members, so an independent never counts as breaking with a party.
Establishes the total amount of revenue each type of generic user fee shall generate.
Authorizes the Secretary to accept payment of user fees prior to their due date.
(Sec. 203) Extends requirements for the FDA to report to Congress on achieving goals related to the generic animal drug development and review process and the implementation of the authority to collect generic animal drug fees.
(Sec. 206) Terminates the authority to collect generic animal drug user fees October 1, 2018.
Written by the nonpartisan Congressional Research Service, describing S. 622 as public Law on Jun 13, 2013. It is not the text of the measure; a later amendment may have changed what it does.
Organizations that named S. 622 in a lobbying disclosure. Only those that cited the bill by number appear, so this is a floor, not a full list.
110 disclosures name this measure. Retrieved from LDA.gov on 2026-10-05. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.